Document is current
Any future updates will be listed below
-
Authors
McNeel, Douglas G https://orcid.org/0000-0003-1471-6723
Eickhoff, Jens C
Wargowski, Ellen
Johnson, Laura E
Kyriakopoulos, Christos E https://orcid.org/0000-0002-6452-7405
Emamekhoo, Hamid
Lang, Joshua M
Brennan, Mary Jane
Liu, Glenn
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02499835 at ClinicalTrials.govnct04090528 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
https://doi.org/10.1136/jitc-2021-004198
Documents that mention this clinical trial
499 Phase 2 trial of pTVG-HP DNA vaccine, with or without pTVG-AR DNA vaccine, and pembrolizumab in patients with castration-resistant, metastatic prostate cancer
https://doi.org/10.1136/jitc-2025-sitc2025.0499
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
https://doi.org/10.1136/jitc-2021-004198
-
Funding
Funding for this research was provided by:
Madison Vaccines Inc.
National Cancer Institute (P30 CA014520)
National Cancer Institute (R01 CA129154)
Prostate Cancer Foundation (2014 Movember-PCF Challenge Award)
- License Information
